CORRECTIONAL PSYCHIATRY
PRACTICE GUIDELINES AND STRATEGIES

Ole J. Thienhaus, M.D., M.B.A.
and
Melissa Piasecki, M.D.
CORRECTIONAL PSYCHIATRY
PRACTICE GUIDELINES AND STRATEGIES

Edited by
Ole J. Thienhaus, M.D., M.B.A.
and
Melissa Piasecki, M.D.

Civic Research Institute
4478 U.S. Route 27 • P.O. Box 585 • Kingston, NJ 08528
# Table of Contents

About the Editors and Authors .............................................................. v  
Foreword ......................................................................................... ix  
Introduction .................................................................................... xiii  

## PART 1: THE SETTING

### Chapter 1: Setting the Stage—A Brief History of Detention Centers and Mental Illness in the United States  
*M. Nathan Mason, M.D.*

Introduction ....................................................................................... 1-1  
The Early Years ................................................................................ 1-2  
Reforms in the Later Nineteenth Century ........................................... 1-3  
Mental Illness in Eighteenth- and Nineteenth-Century America .......... 1-4  
Developments in Incarceration in the Twentieth Century .................... 1-7  
Current Status and Challenges Ahead .............................................. 1-11  
Summary .......................................................................................... 1-13

### Chapter 2: Impact of the Structure and Function of Corrections on Inmates’ Mental Health  
*James Knoll IV, M.D.*

Introduction ....................................................................................... 2-2  
The Function of Corrections ............................................................. 2-3  
- Theories of Punishment .................................................................. 2-3  
- Rehabilitation ............................................................................... 2-3  
- Restraint ....................................................................................... 2-4  
- Retribution .................................................................................... 2-4  
- Deterrence .................................................................................... 2-4  
- Function of Custody ..................................................................... 2-5  
- Custodial Methods ....................................................................... 2-6  
Jails ...................................................................................................... 2-8  
Prisons ................................................................................................ 2-9  
- Minimum Security ........................................................................ 2-10  
- Medium Security ......................................................................... 2-10  
- Maximum Security ....................................................................... 2-10  
- Supermax Custody ....................................................................... 2-11  
- Intermediate Care Units ............................................................... 2-12  
Alternatives to Incarceration ............................................................ 2-13  
- Probation and Parole .................................................................... 2-13
Chapter 3: Key Considerations in Liability Management and the Correctional Psychiatrist

Henry A. Dlugacz, J.D., M.S.W. and Julie Y. Low, M.D.

Introduction ................................................................. 3-1

The Laws Under Which a Psychiatrist Operates ......................... 3-3

Federal Constitutional Standards ........................................ 3-3

How the Constitutional Standard Developed in Historical Context ......................................................... 3-3

Early Cases ................................................................. 3-5

Deliberate Indifference Standard ........................................ 3-6

How *Gamble* Standard Affected Mental Health Care ................ 3-6

Evolution of the *Gamble* Standard .................................... 3-7

Meaning of “Deliberate Indifference” .................................. 3-8

General Principles Drawn From Case Law ................................ 3-9

Statutes and Standards .................................................. 3-11

Americans With Disabilities Act ....................................... 3-11

State Law Governing Mental Health Practice ......................... 3-12

Local Law Regulating Correctional Practice ......................... 3-13

Professional Standards ................................................ 3-13

Clinical Ramifications of the Law ...................................... 3-14

Appropriate Documentation ............................................ 3-14

Suicidality/Suicide Risk ................................................. 3-16

Fostering Consistency of Care ........................................ 3-19

Criminal Justice System/Correctional Institution Issues ................. 3-20

Conclusion ...................................................................... 3-21
PART 2: THE PRACTICE OF PSYCHIATRY IN CORRECTIONAL FACILITIES

Chapter 4: Addressing Inmate Sleep Disorders
*Ole J. Thienhaus, M.D., M.B.A.*

Introduction ................................................................. 4-1
Assessment of Insomnia: Making a Diagnosis ..................... 4-2
  Primary Insomnia ......................................................... 4-2
  Situational and Environmental Contributing Factors .......... 4-3
  Therapeutic Responses ............................................... 4-3
Sleep Disorders Related to Another Mental Disorder .......... 4-4
  Insomnia as a Warning Sign ....................................... 4-4
  Insomnia as an Associated Symptom ............................ 4-4
Sleep Disorders Due to a General Medical Condition ......... 4-5
Substance-Induced Sleep Disorders ................................. 4-5
Treatment ........................................................................ 4-5
  Nonpharmacological Interventions ............................... 4-6
    Environmental Intervention ..................................... 4-6
    Sleep Hygiene Education ......................................... 4-6
    Behavioral Therapy ................................................ 4-6
  Pharmacological Treatment ........................................ 4-6
Conclusion ........................................................................ 4-7

Chapter 5: Treating Intoxication and Withdrawal
*Dana M. Arlien, M.D. and John N. Chappel, M.D., M.P.H.*

Introduction ...................................................................... 5-2
Intoxication vs. Withdrawal ............................................ 5-3
Substance Use Disorders in Correctional Populations: An Overview ............................................. 5-3
  Prevalence ..................................................................... 5-3
  Screening ....................................................................... 5-4
  Treatment Referral ...................................................... 5-6
Alcohol Withdrawal ........................................................ 5-6
  Symptoms of Alcohol Withdrawal ................................ 5-7
  Treatment of Alcohol Withdrawal ................................ 5-7
    Symptom-Triggered Therapy ...................................... 5-8
    Fixed-Dose Therapy ................................................ 5-11
    Frontloading ........................................................... 5-12
    Benzodiazepine Treatment ........................................ 5-12
    Valproic Acid Treatment ........................................... 5-13
Chapter 6: Suicide Risk Management in the Correctional Setting
Ole J. Thienhaus, M.D., M.B.A.

Scope of the Problem .......................................................... 6-1
Risk Assessment ................................................................. 6-3
  Current Situational Context ............................................... 6-4
  Location on the Continuum of Suicidality ............................ 6-4
  Coexisting Psychopathology .............................................. 6-4
  History of Attempted Suicide ........................................... 6-4
  Nature of the Suicide Plan ............................................... 6-5
  Deterrents ................................................................. 6-5
  “Manipulative Behavior” or “Suicidal Gesture” ....................... 6-5
  Future Perspective ........................................................ 6-5
  Impact of the Interview .................................................. 6-6
  The Risk of Intoxication .................................................. 6-6
Involvement of Other Clinicians ........................................... 6-6
  Value of a Second Opinion ............................................... 6-6
  Documentation of Dispositional Decision and Its Rationale ....... 6-6
Risk Management .............................................................. 6-7
  Institutional Protocol ..................................................... 6-7
  Therapeutic Response ...................................................... 6-7
  APA Guidelines ............................................................ 6-8
Dealing With the Aftermath of a Suicide ................................. 6-9
Conclusion ........................................................................ 6-10

Chapter 7: Behavioral Prescriptions for Treating Self-Injurious and Suicidal Behaviors
Henry Schmidt III, Ph.D. and Andre Ivanoff, Ph.D.

Introduction .................................................................. 7-2
Preventing Self-Injury and Suicidal Behaviors ......................... 7-2
  Staffing Implications ....................................................... 7-2
  Recognizing a Continuum of Behaviors .............................. 7-3
  Limits of Screening Instruments ...................................... 7-4
Treatment of Self-Injurious Behavior ...................................... 7-5
  General Procedures ....................................................... 7-6
Chapter 8: Hunger Strikes in Correctional Facilities

Michael K. Daines, M.D.

Introduction ...................................................... 8-1
Historical Perspective ........................................ 8-1
Legal Right to a Hunger Strike ........................... 8-2
Scope of the Problem .......................................... 8-4
  Prevalence .................................................. 8-4
  Definition ................................................... 8-4
  Impact on the Correctional System ................. 8-5
The Role of the Psychiatrist ............................... 8-5
  Determining Motivation ................................ 8-5
  Maintaining Medical Stability ....................... 8-6
  Assessing Capacity for Medical Decision Making 8-7
Psychiatric Diagnosis and Treatment of Hunger Strikes 8-8
  General Treatment Principles ....................... 8-8
  Major Depressive Disorder ......................... 8-9
  Psychoses .................................................. 8-10
Eating Disorders ......................................................... 8-11
Personality Disorders ............................................... 8-11
Conclusion ............................................................... 8-12

Chapter 9: Malingering in Correctional Settings
Steven J. Zuchowski, M.D. and Philip J. Resnick, M.D.
Introduction ............................................................... 9-1
Common Motives for Malingering ................................ 9-2
Primary vs. Secondary Gain ........................................ 9-2
Secondary-Gain Objectives in Correctional Populations .... 9-3
Subtypes of Malingering .............................................. 9-4
Pure and Partial Malingering ....................................... 9-4
False Imputation ......................................................... 9-4
Malingering vs. Factitious Disorder .................. 9-5
Ganser’s Syndrome vs. Malingering ......................... 9-5
Relationship of Malingering to Antisocial Personality Disorder .... 9-6
Detecting Malingering in Correctional Settings .......... 9-7
Baseline Level of Suspicion Necessary .................... 9-7
Understanding the True Illness Helpful ..................... 9-8
Greater Exposure to Suspected Malingers Useful .......... 9-9
Psychological Tests for Malingering ....................... 9-9
Confronting Suspected Malingers in Correctional Settings .... 9-10
Conclusions ............................................................... 9-11

Chapter 10: Psychiatric Conditions Secondary to Chemical Dependence
Eugene Wang, M.D., Dawn Kishi, J.D. and John T. Frederick, M.D.
Introduction ............................................................... 10-1
Substance-Related Disorders in DSM-IV-TR ............... 10-3
 Substance Use Disorders ............................................ 10-4
 Substance-Induced Disorders .................................. 10-4
 Substance-Induced Persisting Dementia .................. 10-4
 Substance-Induced Persisting Amnestic Disorder .. 10-5
 Substance-Induced Mood Disorder ......................... 10-6
 Substance-Induced Psychotic Disorder ................... 10-7
 Methamphetamine Psychosis .................................. 10-9
Conditions Associated With Substance Use ............... 10-12
 Dual Diagnosis ......................................................... 10-12
 Antisocial Behavior and Psychopathy ..................... 10-13
Assessment Issues .................................................... 10-14
Treatment Issues ................................................................. 10-15
  Dilemma of Right to Treatment ..................................... 10-15
  Lineage of Case Law ..................................................... 10-15
  Federal Bureau of Prisons ............................................. 10-17
  Challenges ..................................................................... 10-17
Conclusion ........................................................................ 10-17

Chapter 11: Countertransference in Correctional Settings
Gregory Brown, M.D.
Introduction ...................................................................... 11-1
Definitions .......................................................................... 11-2
  Transference .................................................................... 11-2
  Countertransference ........................................................ 11-3
Challenges Within the Correctional Setting ......................... 11-3
Common Countertransference Issues in the Correctional Setting
  Fear .................................................................................. 11-5
  Denial of Fear ................................................................. 11-5
  Becoming the Advocate ..................................................... 11-5
  The Puppet ....................................................................... 11-6
  Inability to Trust ............................................................. 11-6
  Desire to Punish ............................................................... 11-7
  Guilt .................................................................................. 11-7
  Disdain and Emotional Separation ..................................... 11-7
Challenges When Working With Special Populations ............. 11-8
  Antisocial Personality Disorder ......................................... 11-8
  Narcissism ........................................................................ 11-9
  Sex Offenders .................................................................... 11-9
Managing Countertransference ........................................... 11-10
Summary ............................................................................. 11-11

Chapter 12: Implementing Reentry—Establishing a Continuum of Care of Adult Jail and Prison Releasees With Mental Illness
Henry A. Dlugacz, J.D., M.S.W., Nahama Broner, Ph.D. and Stacy S. Lamon, Ph.D.
Introduction ....................................................................... 12-2
  Arrest and Release Rates .................................................. 12-3
  Prevalence of Mental and Addictive Disorders ..................... 12-3
  Availability of Correctional Assessment and Treatment .......... 12-4
Development and Status of Reentry Planning ......................... 12-6
Criminal Justice Services Linkage Models ............................. 12-8
Evolution of the Continuum of Care ..................................... 12-9
TABLE OF CONTENTS

Professional Standards .................................................. 12-11
Fledgling Litigation ..................................................... 12-12
Emerging View of Correctional Mental Health ....................... 12-14
Financial Benefit of Reentry Programming .......................... 12-14
Public Safety ..................................................................... 12-15
Creating Reentry Programs ............................................. 12-16
  Role of the Psychiatrist in Reentry Planning ....................... 12-17
  Assessing Community Resources .................................... 12-17
  Collaborative Stakeholder Consensus Building—
    The Crucial “Buy-in” .................................................. 12-18
Screening and Assessment .............................................. 12-19
  Screening Instruments .................................................. 12-20
  Assessment Domains .................................................... 12-21
  Assessment Instruments .............................................. 12-23
Medication Continuity .................................................... 12-24
Practical Considerations—Implementing Reentry .................. 12-25
  Basic Parameters ........................................................ 12-25
  Institutional-Cultural Perspective .................................. 12-26
  Population to Be Served .............................................. 12-26
  Identifying the Population .......................................... 12-27
Understanding the Larger Correctional and Community Mental
  Health Systems .......................................................... 12-27
  The Environment for Reentry ....................................... 12-27
    Medication in Transition .......................................... 12-28
    Housing .................................................................... 12-28
    Ability to Pay for Services ...................................... 12-29
Tracking of Initial Reentry ............................................. 12-29
Conclusion ...................................................................... 12-30

PART 3: SPECIAL POPULATIONS

Chapter 13: Mental Health Care of Juveniles in Adult Correctional
Facilities
Todd Elwyn, J.D., M.D. and Erika Ryst, M.D.

Introduction ................................................................. 13-2
Characteristics of Youthful Offenders ................................ 13-2
  Demographic Information ........................................... 13-2
  Mental Health Information ........................................... 13-4
Numbers of Juveniles in Adult Facilities ............................ 13-6
How Juveniles End Up in Adult Facilities ........................... 13-6
Problems of Juveniles in Adult Prisons ............................................. 13-7
Issues in Mental Health Assessment, Diagnosis, and
Treatment .................................................................................. 13-8
Treatment of Specific Mental Health Conditions ...................... 13-9
Conduct Disorder ...................................................................... 13-9
  Background .............................................................................. 13-9
  Assessment ............................................................................. 13-10
  Treatment .............................................................................. 13-11
Attention Deficit Hyperactivity Disorder .................................. 13-12
  Background .............................................................................. 13-12
  Assessment ............................................................................. 13-12
  Treatment .............................................................................. 13-13
Substance Use Disorders ............................................................ 13-14
  Background .............................................................................. 13-14
  Assessment ............................................................................. 13-15
  Treatment .............................................................................. 13-16
Anxiety Disorders and Posttraumatic Stress Disorder ................. 13-16
  Background .............................................................................. 13-16
  Assessment ............................................................................. 13-17
  Treatment .............................................................................. 13-18
Mood Disorders ......................................................................... 13-18
  Background .............................................................................. 13-18
  Assessment ............................................................................. 13-19
  Treatment .............................................................................. 13-20
Psychotic Disorders ................................................................... 13-21
  Background .............................................................................. 13-21
  Assessment ............................................................................. 13-22
  Treatment .............................................................................. 13-23
Conclusion .................................................................................. 13-24

Chapter 14: Working With Individuals Who Have Intellectual
Disabilities
Coni Kalinowski, M.D.
Introduction ................................................................................ 14-1
Relationship Between Intellectual Disabilities and Criminality .......... 14-3
  Prevalence of Criminal Behavior ............................................. 14-3
    Possibility of Comorbid Antisocial Personality Disorder .......... 14-4
Identification of Criminal Behavior in Individuals With
Intellectual Disabilities ................................................................. 14-5
Epidemiology of Intellectual Disabilities in the Criminal Justice
System ....................................................................................... 14-6
Vulnerability Within the Criminal Justice System .............................................. 14-7
Characteristics of Offenders With Intellectual Disabilities .......................... 14-7
Offense Patterns .............................................................................................. 14-9
   Types and Severity of Offenses ................................................................. 14-9
   Recidivism ................................................................................................. 14-10
Dual Diagnosis ............................................................................................... 14-10
Diversion .......................................................................................................... 14-11
   Treatment Modalities in Diversion Programs ......................................... 14-12
   Barriers to Effective Diversion Strategies ............................................. 14-13
Medical, Psychiatric, and Substance Abuse Treatment ............................... 14-13
   Adaptation of Inmates With Intellectual Disabilities to Incarceration .... 14-14
   Autistic Spectrum Disorders .................................................................. 14-15
   Fetal Alcohol Syndrome ....................................................................... 14-16
Summary .......................................................................................................... 14-17

Chapter 15: Psychiatric Care of Incarcerated Women
Melissa Piasecki, M.D.
Introduction ................................................................................................. 15-2
   Demographics of Incarcerated Women .................................................. 15-2
   Population ................................................................................................. 15-3
   Types of Offenses ................................................................................. 15-3
   Impact of Motherhood ........................................................................... 15-4
   Pregnancy ................................................................................................. 15-4
Psychiatric Diagnoses in Incarcerated Women ........................................... 15-5
   Substance Use Disorders ....................................................................... 15-5
   Substance Use and Co-occurring Disorders ......................................... 15-6
   Trauma-Related Disorders .................................................................. 15-6
   Personality Disorders ........................................................................... 15-7
Mental Health Service Provision in Jails .................................................... 15-7
Assessments ................................................................................................. 15-8
   Mental Health Needs ............................................................................ 15-8
   Self-Harm Behavior Assessment ......................................................... 15-8
   Medical Assessment ............................................................................. 15-9
   Pregnancy Screen ............................................................................... 15-10
   Stressors ................................................................................................. 15-10
Treatment of Incarcerated Women ............................................................. 15-11
Pharmacotherapy ....................................................................................... 15-11
   Medications for Depression and Anxiety ........................................... 15-12
   Medications for Bipolar Disorder ....................................................... 15-13
   Medications for Psychotic Disorders ................................................ 15-14
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Geriatric Patients</td>
<td>16-1</td>
</tr>
<tr>
<td></td>
<td>Ole J. Thienhaus, M.D., M.B.A.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>16-1</td>
</tr>
<tr>
<td></td>
<td>Homeostasis</td>
<td>16-2</td>
</tr>
<tr>
<td></td>
<td>Common Psychiatric Pathology in Late Life</td>
<td>16-3</td>
</tr>
<tr>
<td></td>
<td>Depressive Disorders</td>
<td>16-3</td>
</tr>
<tr>
<td></td>
<td>Differential Diagnoses</td>
<td>16-3</td>
</tr>
<tr>
<td></td>
<td>Treatment Considerations</td>
<td>16-4</td>
</tr>
<tr>
<td></td>
<td>Pharmacological Interventions</td>
<td>16-5</td>
</tr>
<tr>
<td></td>
<td>Cognitive Disorders</td>
<td>16-6</td>
</tr>
<tr>
<td></td>
<td>Differential Diagnoses</td>
<td>16-6</td>
</tr>
<tr>
<td></td>
<td>Treatment Considerations</td>
<td>16-7</td>
</tr>
<tr>
<td></td>
<td>Pharmacological Interventions</td>
<td>16-7</td>
</tr>
<tr>
<td></td>
<td>Psychosis</td>
<td>16-8</td>
</tr>
<tr>
<td></td>
<td>Conclusion</td>
<td>16-9</td>
</tr>
<tr>
<td>17</td>
<td>Treatment of Sex Offenders in a Correctional Setting</td>
<td>17-2</td>
</tr>
<tr>
<td></td>
<td>Ian Heath, M.D., C.M.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>17-2</td>
</tr>
<tr>
<td></td>
<td>Who Are Sex Offenders?</td>
<td>17-2</td>
</tr>
<tr>
<td></td>
<td>A Heterogeneous Group</td>
<td>17-2</td>
</tr>
<tr>
<td></td>
<td>Typologies of Sex Offenders</td>
<td>17-3</td>
</tr>
<tr>
<td></td>
<td>What Are Paraphilias?</td>
<td>17-4</td>
</tr>
<tr>
<td></td>
<td>Risk Appraisal</td>
<td>17-4</td>
</tr>
<tr>
<td></td>
<td>Assessment Methods</td>
<td>17-5</td>
</tr>
<tr>
<td></td>
<td>Which Risk Factors Correlate With Sexual Recidivism?</td>
<td>17-5</td>
</tr>
<tr>
<td></td>
<td>Actuarial Instruments</td>
<td>17-8</td>
</tr>
<tr>
<td></td>
<td>Reliability</td>
<td>17-8</td>
</tr>
<tr>
<td></td>
<td>RRASOR</td>
<td>17-8</td>
</tr>
<tr>
<td></td>
<td>Static-99</td>
<td>17-9</td>
</tr>
<tr>
<td></td>
<td>MnSOST-R</td>
<td>17-9</td>
</tr>
</tbody>
</table>
PART 4: ETHICS

Chapter 19: The Red Zone—Boundaries of Clinical vs. Forensic Work in Correctional Settings
Kathryn A. Burns, M.D., M.P.H.
Introduction .................................................. 19-1
Medical Ethics vs. Forensic Ethics ................... 19-2
  Traditional Medical Ethics .......................... 19-2
  Forensic Ethics .................................. 19-3
Dual Agency and Correctional Psychiatry ........... 19-3
  Potential Conflict .................................. 19-3
  Confidentiality Concerns .......................... 19-4
    Correctional Modifications to Confidentiality .......... 19-4
    Limited Disclosure to Security Personnel .......... 19-4
Role of the Psychiatrist in the Inmate Disciplinary Process .................................. 19-5
  Assessment of Inmate Competency to Proceed ........ 19-5
  Psychiatric Mitigating Factors and Dispositional Recommendations ........ 19-6
Administrative Segregation .......................... 19-7
  Preplacement Mental Health Evaluations ................ 19-7
  Classification Committee Periodic Review ............ 19-7
Parole Evaluations ................................ 19-8
Death Row ............................................ 19-9
  General Psychiatric Evaluation and Treatment .......... 19-9
  Determination of Prisoner Competence for Execution .......... 19-9
  Treatment to Restore Competency for Execution .......... 19-9
Summary ............................................ 19-10

Chapter 20: Research With Prisoners
Robert L. Trestman, Ph.D., M.D.
Introduction ............................................... 20-1
  Background ........................................ 20-1
  Why Correctional Mental Health Research Is Needed .......... 20-2
History of Prisoner Research .......................... 20-3
Ethics and Current Guidelines ........................ 20-3
Pragmatics of Current Research With Mentally Ill Prisoners ........ 20-5
Preclinical Research ......................................................... 20-6
Clinical Research ......................................................... 20-7
Translational Research .................................................... 20-9
Policy, Economics, and Public Health .............................. 20-10
Summary ................................................................. 20-10

Appendix A: Organizations of Interest ................................. A-1
Appendix B: Glossary of Key Technical Terms ...................... A-5
Appendix C: Bibliography ................................................ A-9

Index ................................................................. I-1
Introduction

On any given day, 2.2 million people are incarcerated in the United States, and over the course of a year, an estimated 13.5 million individuals spend time in prison or jail. 750,000 men and women work in these facilities. The annual cost: [amounts to] more than 60 billion dollars. At this moment, the effectiveness and decency of America’s approach to corrections has the attention of policy makers at all levels of government and in both political parties. Now is the right time for a national discussion about the most serious problems of life behind bars and for constructive recommendations for reform.

— Commission on Safety and Abuse in America’s Prisons
www.prisoncommission.org (accessed April 11, 2006)

More than 2 million people are incarcerated in the United States, and a disproportionately high number of them suffer from mental illness. In some areas (e.g., in Nevada) the number of psychiatric inpatient beds in facilities of the Department of Corrections exceeds the number of hospital beds controlled by the state mental health system. Given the epidemiological proportions and the specific circumstances of delivering psychiatric care in jails and prisons, the dearth of pertinent textbooks and practitioner desk references is surprising.

We decided to put together this book after practicing correctional psychiatry for a few years at a detention center in Reno and a maximum-security prison in California (OJT). General psychiatric residents and third-year medical students were starting to participate in the clinical services we provided, and we hoped to direct them to a clinically oriented resource for information about incarcerated psychiatric patients and how to treat them. At the time, we found a few texts that addressed the psychological assessment of incarcerated patients and some peer-reviewed articles, but no clinically oriented books.

After we had decided to proceed with a book, we were lucky to find willing chapter authors with expertise in special topics and subpopulations. We are grateful to them and to Civic Research Institute for allowing this text to grow into its current form, and Dr. Jeffrey Metzner for his good advice and support. Our goal is to provide practical information for the general psychiatrist or general practitioner in the correctional setting. To treat patients in jails and prisons effectively we believe the physician must have understandings of the common clinical problems and how to manage them. The legal and ethical context of correctional psychiatry is unlike most other settings. The contextual factors inform all clinical discussions in this book but also merited dedicated chapters on select topics.

This volume tries to address each topic area in a comprehensive manner. It is necessarily incomplete in scope, failing to address a number of relevant areas of concern. For instance, the specific issue of minorities and their psychiatric needs, the problem of gangs in prison settings as they can contribute to mental health issues, and the notoriously difficult challenge of transitioning mentally ill inmates out of the correctional
setting into the community all deserve discussion. Similarly, the complex organizational and ethical problems of practicing in a resource-controlled, coercive environment appear repeatedly in the present text but should be dissected on their own merits as well. We refer the reader to a planned second volume that will complement the current book to provide a truly comprehensive resource on all aspects of this important and growing field of clinical practice.

— Melissa Piasecki and Ole J. Thienhaus
February 2007
Index

[References are to pages.]

A
AACFP. See American Association for Correctional and Forensic Psychology
AACP. See American Association of Community Psychiatrists
AAPL. See American Academy of Psychiatry and the Law
“Abnormal illness-affirming behavior,” 9-5
factitious disorder, 9-5–9-6
malingering. See Malingering
ACA. See American Correctional Association
Acquired immunodeficiency syndrome. See HIV/AIDS
ACT. See Assertive Community Treatment
ADA. See Americans with Disabilities Act
ADHD. See Attention deficit hyperactivity disorder
Adjunctive agents, for alcohol withdrawal treatment, 5-13
Administrative segregation
classification committee periodic review, 19-7–19-8
description of, 18-4, 19-7
evolution of, 1-8
preplacement mental health evaluation, 19-7
reasons for, 2-7
responsibility for, 18-4
Affective disorders. See Mood disorders
African Americans
arrest rates, 12-3
juvenile offenders in adult corrections, 13-2–13-4
women, incarcerated, 15-2
Age, sexual recidivism and, 17-7–17-8
Agitation
CIWA-Ar scale, 5-10
sedation for, 16-8
Alcatraz Island level 6 unit, 1-8
Alcohol use disorders
See also Alcohol withdrawal
alcoholism, genetic factors in, 10-13
alcohol-related neurodevelopmental disorder, 14-16
dependence, mood disorders and, 10-7
incarcerated women and, 15-5
interaction with cocaine, 5-21
intoxication, suicide risk and, 6-6
with mental disorders, 10-12–10-13
mood disorders related to, 10-7
substance-induced sleep disorders and, 4-5
Alcohol withdrawal, 5-6–5-16
with cocaine withdrawal, 5-23
complications, 5-13–5-16
delirium, 5-15–5-16
psychological factors, 5-16
psychotic disorder, 5-14
seizures, 5-14–5-15
Wernicke’s encephalopathy, 5-16
definition of, 5-6
duration of symptoms, 5-7
evaluation for, 5-6–5-7
severe, risk factors for, 5-14
stages of, 5-8
symptoms of, 5-6–5-7, 10-7
treatment
fixed-dose therapy, 5-11–5-13
initial, 5-7
medications for, 5-7–5-8
symptom-triggered therapy, 5-8–5-11
ALEC. See American Legislative Exchange Council
Alford pleas, 11-5
Alzheimer’s disease, 16-7
AMA. See American Medical Association
American Academy of Child and Adolescent Psychiatry (AACAP), 13-8–13-9
Amphetamines
  delusional disorder, diagnostic criteria, 10-8
  half-life, 5-20
  intoxication, 5-20–5-21
  overdose/toxicity, treatment of, 5-21, 5-23
  psychosis, 10-9–10-12
  biological predisposition, 10-11
  EEG changes, 10-11
  recurrence, 10-11–10-12
  symptoms, schizophrenia symptoms and, 10-10
  substance-induced sleep disorders and, 4-5
  withdrawal
    diagnostic criteria, 5-23
    phases of, 5-23
    symptoms of, 5-23
  Anorexia nervosa, 8-11
  Antiandrogens
    for sex offender treatment, 17-15–17-18
    sexual recidivism and, 17-8
  Anticonvulsants
    for seizure prevention, in alcohol withdrawal, 5-15
INDEX

[References are to pages.]

Arson, intellectually disabled offenders and, 14-9–14-10
ASPD. See Antisocial personality disorder
Assertive Community Treatment (ACT), 12-15, App.-5
Assessment, of substance use disorders, of juvenile offenders, 13-15
Assessment instruments
See also specific assessment instruments
for attention deficit hyperactivity disorder, 13-13
for bipolar disorder in juvenile offenders, 13-20
for reentry program, 12-23–12-24
Attention deficit hyperactivity disorder (ADHD)
with conduct disorder, 13-9
in juvenile offenders, 13-12–13-14
assessment of, 13-12–13-13
comorbidity, 13-12
onset of, 13-12
treatment, 13-8, 13-13–13-14
misdiagnosis, 13-20
Auditory disturbances, CIWA-Ar scale, 5-10
Autistic spectrum disorders, in intellectually disabled offenders, 14-15–14-16
Autonomic hyperactivity, 5-17
Awl, Dr. William, 1-5

B
“Baby rapers,” 2-26
Barbiturates, 5-16
Bates, Sanford, 1-7
BCA. See Behavioral chain analysis
BDI. See Beck Depression Inventory
Beck Depression Inventory (BDI), 13-19–13-20, 15-15
Beck Hopelessness Scale, 15-9
Beck Depression Inventory, 13-19
Behavioral chain analysis (BCA)
components of, 7-14
cues, 7-15
identifying vulnerabilities, 7-15
links, 7-15–7-16
outcomes, 7-16
target behaviors, 7-16
evaluating risk of future self-injurious behavior, 7-20–7-21
narrative development, 7-15
twenty-four hour rule and, 7-13
Behavioral incentive programs, 18-15–18-16
Behavioral therapy
See also Cognitive-behavioral therapy
for ADHD, 13-14
for intellectually disabled offenders, 14-12
for sleep improvement, 4-6
Belmont Report, 20-4
Beneficence, traditional medical ethics and, 19-2
Benzodiazepines
for alcohol withdrawal treatment, 5-7–5-8, 5-12–5-13
for anxiety treatment, 13-18
for cognitive disorders, 16-8
intoxication, 5-16
for seizure prevention, in alcohol withdrawal, 5-15
for sleep disorders, 4-6–4-7
use in correctional setting, 15-13
withdrawal, 5-16–5-17
symptom rebound, 5-17
symptoms of, 5-17
treatment of, 5-17
Beta-blockers, for alcohol withdrawal treatment, 5-13
Biomedical research, standards for, 20-5
Bipolar disorder
in children and adolescents, 13-20
differential diagnosis, 13-22–13-23
pharmacotherapy, 15-13–15-14
with substance abuse, prisoner research on, 20-8
Black market, in correctional facilities, 2-23
Blended sentencing, 13-7
Blood urea nitrogen (BUN), 16-2
Boot camps, for shock incarceration, 2-14
Borderline personality disorder (BPD)
dialectical behavior therapy for, 7-19
hunger strikes and, 8-12
incarcerated women and, 15-7
Brief Jail Mental Health Screen, 12-21
Brief Symptom Inventory, 15-6
BUN. See Blood urea nitrogen
Buprenorphine, for opioid detoxification, 5-18–5-19
Bupropion, 16-6

C
Caffeine, substance-induced sleep disorders and, 4-5
California Department of Corrections (CDC), 1-11
California Department of Corrections and Rehabilitation (CDCR), 18-9–18-11
Cannabis. See Marijuana
Capacity assessment, during hunger strike, 8-7–8-8
Carbamazepine for alcohol withdrawal treatment, 5-13
for juvenile bipolar disorder, 13-21
for seizure prevention, in alcohol withdrawal, 5-15
Cardiomyopathy, 8-7
Case law
Allegheny City Jail v. Pierce, 18-2
Banning v. Looney, 3-4, 12-6
Bell v. Wolfish, 2-18, 3-13
Bieber v. People, 10-8
Bowring v. Godwin, 1-10, 10-3, 10-15, 10-16, 18-2
Bowring v. Mills, 3-6–3-7
Brad H. v. City of New York, 12-7, 12-13–12-14
California v. Stewart, 14-7
Coleman v. Wilson, 1-2, 1-11, 18-14
Deshaney v. Winnebago Dep’t of Social Services, 12-12, 12-13
Dusky v. United States, 9-3
Estelle v. Gamble, 1-10, 3-6, 10-3, 10-15, 12-12–12-13, 18-2
Farmer v. Brennan, 3-8
Ford v. Wainwright, 19-9
general principles from, 3-9–3-11
Georgia, United States v., 3-12
Gibson v. County of Washoe, Nevada, 3-8
Grand Jury Subpoena of John Doe, In re 8-4
Jeter, State v., 10-17
Johnson, State v., 10-17
Jones ’El v. Barge, 2-11
Kansas v. Hendricks, 11-9
Koch v. Lewis, 2-11
Madrid v. Gomez, 2-11, 3-8–3-9
Martinez v. Turner, 8-3
Miranda v. Arizona, 14-7
Montana v. Egelhoff, 10-3
Newman v. Alabama, 3-5–3-6
Pennsylvania Dep’t of Corrections v. Yeskey, 3-11
Perry, State v., 19-10
Plata v. Davis, 1-11
Rhodes v. Chapman, 2-18
Riddle v. Mondragon, 10-16
Rohan ex rel. Gates v. Woodford, 9-3
Ruíz v. Estelle, 1-10–1-11, 3-7, 18-2
Sandin v. Conner, 2-11
Schloendorff v. Society of New York Hospital, 3-15
Tarasoff v. Regents of the University of California, 3-3
Tony Goodman v. Georgia, 3-12
Turner v. Saflay, 2-5
Vignera v. New York, 14-7
Wakefield v. Thompson, 12-7, 12-12, 12-25
Westover v. United States, 14-7
Williams v. Vincents, 3-5–3-6
Wolff v. McDonnell, 19-5
Wyatt v. Stickney, 12-6
Youngberg v. Romeo, 3-10
Case management
in segregated housing, 18-13–18-14
for transition to community services, for women, 15-17–15-18
Cat-and-Mouse Act, 8-2
CBT. See Cognitive-behavioral therapy
CCM. See Clinical case management
CDC. See California Department of Corrections
CDCR. See California Department of Corrections and Rehabilitation
CDI. See Children’s Depression Inventory
Chemical dependence, secondary psychiatric diagnoses, 10-1–10-18
Children, of incarcerated women, 15-4–15-5
Children’s Depression Inventory (CDI), 13-20
Chlordiazepoxide, for alcohol withdrawal treatment, 5-12
Chlorpromazine, 1-10, 4-7, 5-23
Churchill, Winston, 8-2
Civil rights movement, 3-5
Civil Rights of Institutionalized Persons Act (CRIPA), 3-11
CIWA-Ar. See Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised
CJ-DATS. See Criminal Justice Drug Abuse Treatment Studies
Class action litigation, 3-4–3-5
Classification, of inmates, 2-6
Classification committee periodic review, for administrative segregation, 19-7–19-8
Cleveland Dual Diagnosis Screening Instrument, 12-21
Clinical case management (CCM), in segregated housing, 18-13–18-14
Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar), 5-8–5-11
Clinical picture assessment, for reentry program, 12-22
Clinicians. See Physicians; Psychiatrists
Clomipramine, 13-18
Clonidine
for ADHD, 13-13
for alcohol withdrawal treatment, 5-13
for opioid withdrawal, 5-19
Clothing of inmate, suicide risk and, 6-7
Cocaine
half-life, 5-20
interaction with alcohol, 5-21
substance-induced sleep disorders and, 4-5
use at time of offense, 5-4
withdrawal
with alcohol withdrawal, 5-23
symptoms of, 5-23
CODSI. See Co-occurring Disorder Screening Instrument
Cognitive-behavioral therapy (CBT)
for depressive disorders, 16-5
for intellectually disabled offenders, 14-12
for sex offenders, 17-12
for substance abuse for incarcerated women, 15-15–15-16
Cognitive disorders
alcohol-associated, 10-4–10-5
from fetal alcohol syndrome, 14-16–14-17
in geriatric inmates, 16-6–16-8
differential diagnoses, 16-6–16-7
pharmacotherapy, 16-7–16-8
treatment considerations, 16-7
Commitment, involuntary, App.-5–App.-6
Communication, suicidality and, 3-18
Community resources
assessing for reentry planning, 12-17–12-18
stakeholder buy-in for reentry program, 12-18–12-19
Comorbidity. See Dual diagnosis
Competency
assessment
for disciplinary hearing, 19-5–19-6
for execution, 19-9
of intellectually disabled offenders, 14-7
legal standard for, 9-3
Concerta®, 13-14
Conduct disorder
in juvenile offenders
with ADHD, 13-9
assessment of, 13-9–13-10
diagnosis of, 13-9
prevalence rates, 13-9
prognosis for, 13-9
treatment, 13-11–13-12
juvenile offenders and, 13-5
Confidentiality
in correctional setting, 19-4–19-5
limited disclosure to security personnel, 19-4–19-5
medical ethics, correctional modifications of, 19-4
of therapeutic relationship, 18-6–18-7
traditional medical ethics and, 19-2
Confinement, administrative segregation, 19-7–19-8
Conformity pressures, effects in prison environment, 2-28–2-29
Consensus building, with collaborative stakeholders for reentry program, 12-18–12-19
Contingency management, for self-injurious behavior, 7-9–7-10
Controlled movement, as custodial method, 2-6
Co-occurring disorders. See Dual diagnosis
Co-occurring Disorder Screening Instrument (CODSI), 12-21
Correctional facilities, 2-15
black market in, 2-23
consistency of care, fostering, 3-13
dayrooms, 2-15
environment of care, for sex offender treatment, 17-11–17-12
gambling in, 2-23–2-24
linear layout for, 2-15–2-16
medical units, 2-15
Correctional facilities (continued)
pharmacotherapy for sex offenders in,
17-18–17-19
staff. See Corrections officers; Staff
Correctional officers
definition of, 2-18
malignant attitudes, 2-19–2-20
officer-in-charge or OIC, 2-19
professional respect for, 2-18
salaries of, 1-12
sexual abuse, of women inmates, 15-11
us-versus-them mentality and,
2-27
Correctional system
alternatives to incarceration, 2-13–2-14
definition of, 2-2–2-3, 2-31
detention centers. See Jails; Prisons
facilities. See Correctional facilities
function of, 2-3–2-8
custody, 2-5–2-8
punishment, 2-3–2-5
historical aspects of, 2-2
impact of hunger strikes on, 8-5
linkage with reentry program, 12-27
mental health care
emerging view of, 12-14
requirements, general, 18-2–18-3
psychological functioning of, 2-3
staff, 2-18–2-20
structure, 2-14–2-18
antisuicide architecture, 2-16–2-17
design advances, 2-15–2-16
systematic review, 3-20
Council of State Governments (CSG),
App.-2
Countertransference, 11-1–11-11
acknowledgment of, 11-3
in correctional setting
becoming the advocate, 11-5–11-6
challenges, 11-3–11-4
denial of fear, 11-5
desire to punish, 11-7
disdain, 11-7–11-8
emotional separation, 11-7–11-8
fear, 11-5
guilt, 11-7
inability to trust, 11-6–11-7
modification of, 11-4
“the puppet,” 11-6
“countertherapeutic scotomas,” 11-10
definition of, 11-3
management of, 11-10
vs. transference, 11-2
with special populations
antisocial personality disorder, 11-8
narcissism, 11-9
sex offenders, 11-9–11-10
Counts, inmate, 2-6
CPA (cyproterone acetate), for sex offender
treatment, 14-14, 17-16–17-17
Crack. See Cocaine
CRAFFT screening tool, 13-15
Creatinine, serum, 16-2
Crime problem, 2-4
Criminal behavior, intellectual disabilities
and
identification of, 14-5–14-6
prevalence of, 14-3–14-4
Criminal Justice Drug Abuse Treatment
Studies (CJ-DATS), 12-21
CRIPA. See Civil Rights of Institutionalized
Persons Act
Crisis intervention, in segregated housing,
18-12–18-13
CSG. See Council of State Governments
Custody
function of, 2-5–2-6
methods of, 2-6–2-8
protective, 2-7
Cyproterone acetate (CPA), for sex offender
treatment, 14-14, 17-16–17-17
D
Damages, monetary, 3-2
Dayrooms, 2-15
Daytime functioning, sleep disturbances and,
4-10
Daytime sleepiness, primary insomnia and,
4-4
Day treatment, 18-14–18-15
DBT. See dialectical behavior therapy
Death row, 19-9–19-10
Debriefing, after suicide, 6-9–6-10
Decision-making process, liability concerns
and, 3-1–3-2
Declaration in Malta (1992), 8-3
Dehumanization, effects in prison
environment, 2-28–2-29
Dehydration, medical effects of, 8-6–8-7
Deindividuation, effects in prison
environment, 2-28–2-29
Deinstitutionalization, of mentally ill, 1-10
Deliberate indifference standard
Gamble standard, 3-6–3-8
knowledge, requisite level of, 3-8
meaning of, 3-8–3-9
psychiatrists and, 3-2, 3-6
Delirium
alcohol withdrawal, 5-15–5-16
cocaine-induced, 5-21
differential diagnosis, 16-6
stimulant-induced, 5-21
Dementia
alcohol-related, 10-4–10-5
correction of metabolic abnormalities and, 16-7
substance-induced persisting, 10-4–10-5
Department of Health and Human Services (USDHHS), 20-5, 20-9
Depressants, use at time of offense, 5-4
Depressive disorders
See also Major depressive disorder
differential diagnoses, in geriatric inmates, 16-3–16-4
DSM-IV definition of, 16-3
with eating disorder, 8-11
in geriatric inmates, 16-3–16-6
of juvenile offenders, 13-19
pharmacotherapy, 16-5–16-6
broad-spectrum antidepressants, 16-6
in geriatric patients, 16-5–16-6
tricyclic antidepressants, 16-5
for women, 15-12–15-13
in pregnant women, treatment for, 15-13
Deterrence, 2-4–2-5
Detoxification
for alcohol, multiple, seizure risk and, 5-15
for alcohol, valproic acid for, 5-13
definition of, 5-3
symptom-triggered, for alcohol withdrawal, 5-8–5-11
Diagnosis, constitutional care and, 3-9
Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev. (DSM-III-R), diagnostic criteria, for amphetamine delusional disorder, 10-8
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)
Axis IV stressors, suicide risk and, 6-4
definition of major depressive disorder, 16-3
diagnostic criteria, for primary insomnia, 4-9
sleep disorder classification, 4-2
Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. (DSM-IV-TR)
definition
of alcohol withdrawal, 5-6
of paraphilia, 17-4
diagnostic criteria
for amphetamine psychosis, 10-10
for amphetamine withdrawal, 5-23
for antisocial personality disorder, 9-7, 10-13–10-14
for cannabis intoxication, 5-24–5-25
for dependence and withdrawal, 5-3
for hallucinogen intoxication, 5-27
for inhalant intoxication, 5-32
for opioid toxicity, 5-17–5-18
for opioid withdrawal, 5-18
for phencyclidine intoxication, 5-29–5-30
for psychosis NOS, 10-10
for schizophrenia, 13-23
for schizophrenia exclusion, 10-10
for sedative hypnotic or anxiolytic intoxication, 5-16
for sedative hypnotic or anxiolytic withdrawal, 5-16–5-17
for substance-induced persisting amnestic disorder, 10-5–10-6, 10-10
for substance-induced persisting dementia, 10-4, 10-10
for substance-induced persisting mood disorder, 10-6–10-7
for substance-induced psychotic disorder, 10-7–10-8, 10-10
for substance-related disorders, 10-3–10-4
malingering and, 9-1–9-2, 9-7
Diagnostic Interview Schedule III-R, 15-6
Dialectical behavioral therapy, for incarcerated women, 15-16
Dialectical behavior therapy (DBT), 7-19
Diaproex, for juvenile bipolar disorder, 13-21
Diazepam
for alcohol withdrawal treatment, 5-12
for seizure prevention, in alcohol withdrawal, 5-15
Dihydrocodeine. See Opioids
Diphenhydramine, 4-7
Direct supervision model, for correctional facility, 2-16
Disabled persons, discrimination against, right to sue under ADA, 3-12
Discharge planning. See Reentry programs
Disciplinary process
  competency assessment for, 19-5–19-6
  dispositional recommendations, 19-6–19-7
  psychiatric mitigating factors and, 19-6–19-7
  psychiatrist role in, 19-5
Disciplinary segregation, 2-7–2-8
Disdain, of clinician toward inmate, 11-7–11-8
Dispositional recommendations, for disciplinary process, 19-6–19-7
Disruptive behavior disorders, juvenile offenders and, 13-5
Distress tolerance skills, 7-20
Divalproex
  for agitation, 16-8
  for juvenile bipolar disorder, 13-21
Diversion programs
  for intellectually disabled offenders, 14-11–14-13
  barriers to effective strategies, 4-13
  efficacy of, 14-11–14-12
  intervention levels for, 14-11
  treatment modalities in, 14-12–14-13
postbooking, 12-8
prebooking, 12-8
Dix, Dorothea, 1-1, 1-6
Doctor-patient relationship, 11-1–11-2
  abstaining from abusing, traditional medical ethics and, 19-2
  fundamental elements of, 12-11
  quality of, 3-17–3-18
Documentation
  by clinicians, 3-14–3-16
  of consultation or supervision, 3-16
  recordkeeping, constitutional care and, 3-9
  relevant information for, 3-15–3-16
  suicide prevention and, 3-17–3-18
  of suicide risk assessment, 6-6
“Door in the face” strategy, in dealing with self-injurious behavior, 7-9, 7-11
Dopamine, schizophrenia and, 10-9
Double-door system, for correctional facility, 2-14
Down syndrome, 14-2
Doxepine, 4-7
“Do your own time,” 2-21
Drug dependence, prevalence in correctional populations, 5-3–5-4
Drug-related offenses, women and, 15-3–15-4
Drug use, at time of offense, 5-4
DSM-III-R. See Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev., diagnostic criteria, for amphetamine delusional disorder
DSM-IV. See Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
DSM-IV-TR. See Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev.
Dual agency
  definition of, 19-3
  potential conflict and, 19-3–19-4
Dual diagnosis (comorbidity)
  characteristics of inmates with, 10-13
  explanations for, 10-12
  intellectually disabled offenders and, 14-10–14-11
  of juvenile offenders, 13-5
  treatment, 10-12
  treatment program availability for, 12-4–12-5
Due process, 3-12
Duty to preserve life, 8-3

E
Eating disorders, 8-11
ECG. See Electrocardiogram, after hunger strike
Economic factors, in incarceration of mentally ill, 20-10
Ecstasy (MDMA), 10-6
ECST-R. See Evaluation of Competency to Stand Trial–Revised
Education, of incarcerated women, 15-2
Efficacy studies, on prisoners, 20-9–20-10
Eighth Amendment, 10-15–10-16
Electrocardiogram (ECG), after hunger strike, 8-7
Electronic monitoring, 2-13
Emotional separation, of clinician toward inmate, 11-7–11-8
Emotion regulation skills, 7-20
Enhanced outpatient programs, 18-14–18-15
Environment
  interventions, to promote sleep, 4-6
  primary insomnia and, 4-3
Epidemiology, of intellectual disabilities in criminal justice system, 14-6
Escape attempts, facilitation, malingering and, 9-3
Escitalopram, 13-21
Eszopiclone, 4-7
Ethics
  antiandrogens for sex offenders, 17-15
  clinical vs. forensic duties, 17-19
  forensic, 19-3
  medical, traditional, 19-2
  in prisoner research, 20-2–20-5
  of privatization, 1-13
Ethnicity
  of juvenile offenders, 13-5–13-6
  of juvenile offenders in adult corrections, 13-2–13-4
Evaluation of Competency to Stand Trial–Revised (ECST-R), 9-10
Exhibitionism, 17-4
  See also Paraphilias
Extrapyramidal side effects, 16-8

F
Factitious disorder
  vs. Ganser’s syndrome, 9-5–9-6
  vs. malingering, 9-5
Fake Bad Scale, in Minnesota Multiphasic Personality Inventory-2, 9-10
False imputation, malingering and, 9-4–9-5
FAS. See Fetal alcohol syndrome
Fasting. See Hunger strikes
FBI. See Federal Bureau of Investigation
FDA. See Food and Drug Administration
Fear
  denial, by clinician, 11-5
  protective, of clinician, 11-5
Federal Bureau of Investigation (FBI), 17-3
Federal Bureau of Prisons (BOP), App.-2–App.-3
  establishment of, 1-7
  substance abuse treatment and, 10-15, 10-17
Federal constitutional standards, psychiatrists and, 3-2, 3-3
Fentanyl. See Opioids
Fetal alcohol exposure, mental retardation and, 14-2
Fetal alcohol syndrome (FAS), 14-16–14-17
Fetishism, 17-4. See also Paraphilias
First Amendment rights, 8-3
Fixed-dose therapy, for alcohol withdrawal, 5-11–5-13
Fluids, refusal of, 8-7
Fluoxetine, for depression in children, 13-21
Fluvoxamine, 13-18
Food and Drug Administration (FDA), 20-9
“Foot in the door” strategy, in dealing with self-injurious behavior, 7-9, 7-11
Force-feeding, 8-3, 8-4
Forensic ethics, 19-3
Forensic psychiatry, 19-3
Foreseeability, suicide risk and, 6-3
Foreseeability, 3-18
Foster care, for children of incarcerated women, 15-5
Fourteenth Amendment, due process clause, 3-12
Franklin, Benjamin, 1-4
Freedom of speech, hunger strikes and, 8-3
Friends Hospital, Philadelphia PA, 1-5
Frontal lobe syndrome, 16-7
Frontloading, in fixed-dose therapy for alcohol withdrawal, 5-12
Frotteurism, 17-4. See also Paraphilias

G
GAIN. See Global Appraisal of Individual Needs
Gamble standard, 3-6–3-8, 3-12
Gambling, in correctional facilities, 2-23–2-24
Gang affiliation, in prisons, 1-7–1-8, 2-24
Ganser’s syndrome, vs. malingering, 9-5–9-6
Genetics, psychiatric genetics research, 20-7
Geriatric patients, 16-1–16-8
  health care for, 16-1–16-2
  homeostasis and, 16-2–16-3
  population growth, 16-1–16-2
  prevalence, 16-1
  psychiatric pathology, common, 16-3–16-9
  cognitive disorders, 16-6–16-8
  depressive disorders, 16-3–16-6
  psychosis, 16-8–16-9
“Get-tough-on-crime” policy, 2-22
Gladiator Schools, 2-27
Global Appraisal of Individual Needs (GAIN), 12-23
Goserelin, for sex offender treatment, 17-17–17-18
Great Depression, 1-7
Guanfacine, for ADHD, 13-13
Guilt, of clinician, 11-7

H
Hallucinations, auditory
characteristics of, 9-8
malingering and, 9-4
in schizophrenia, 9-4
Hallucinogens, 5-26–5-29
intoxication, 5-27, 5-28
acute adverse reactions, 5-27–5-28
chronic adverse reactions, 5-29
overdose, 5-29
treatment, 5-28–5-29
types of, 5-26–5-27
use at time of offense, 5-4
withdrawal, 5-29
Haloperidol
contraindications, 5-23
for PCP intoxication, 5-31
“Hands-off” doctrine, 3-3–3-4, 3-5
Hare Psychopathy Checklist–Revised (PCL-R), 10-13, 10-14
Headache, CIWA-Ar scale, 5-11
Health Link Program, for incarcerated women with substance abuse problems, 15-17
Hepatitis B, incarcerated women and, 15-10
Hepatitis C
incarcerated women and, 15-10
from in-house tattooing, 2-24
Heroin. See also Opioids
detoxification, 5-19
use at time of offense, 5-4
withdrawal, 5-18
Hispanic juvenile offenders, in adult corrections, 13-3, 13-4
History
of correctional system, 1-1–1-2
of incarceration in twentieth century, 1-7–1-11
of prisons, in early years, 1-2–1-3
HIV/AIDS
incarcerated women and, 15-9–15-10
in prison population, 1-13
“The hole,” solitary confinement in, 2-7–2-8
Homeostasis, geriatric patients and, 16-2–16-3
Homes and Rahe Life Events Stress Scale, 15-10
Homicide, rates, in prison, 2-29
Homosexual contact, in prison population, 1-13
Honesty, forensic ethics and, 19-3
Hopelessness, past suicide attempts and, 15-9
Hormonal agents, for sex offender treatment, 17-15–17-18
Housing
for mentally ill patients, 1-4–1-7
for reentry transition, 12-28–12-29
segregated. See Segregated housing
Human immunodeficiency virus. See HIV/AIDS
Human Rights Watch, 1-12, 15-11
Hunger strikes, 8-1–8-12
capacity assessment for medical decision making, 8-7–8-8
correctional system impact, 8-5
definition of, 8-1, 8-4–8-5
determining motivation for, 8-5–8-6, 8-11–8-12
ethical issues, 8-3–8-4
evaluation process, legal requirements for, 8-8–8-9
historical perspective, 8-1–8-2
impact of, 8-2, 8-5
legal right to, 8-2–8-4
maintaining medical stability during, 8-6–8-7
medical issues, 8-3
prevalence of, 8-4
psychiatric diagnoses and, 8-8–8-12
eating disorders, 8-11
general treatment principles for, 8-8–8-9
major depressive disorder, 8-9–8-10
personality disorders, 8-11–8-12
psychoses, 8-10–8-11
psychiatrist’s role in, 8-5–8-8
refeeding after, 8-7
Hydromorphone. See Opioids
Hydroxyzine, 4-7
Hyperkalemia, 8-7
Hypnotics. See Sedative hypnotics
Hypothalamic-pituitary gonadal axis modulation, for sex offender treatment, 17-14–17-15
Hypothyroidism, lithium-induced, 15-13

I
IBR. See Institute of Behavioral Research
IDEA. See Individuals with Disabilities in Education Act
IDTT. See Interdisciplinary treatment teams
IEP. See individualized educational plan
Imipramine, 1-10
Impulsivity, treatment of, 20-8
Incarceration
adaptation to, intellectually disabled offenders and, 4-14–14-15
alternatives, 2-13–2-14
concept, history of, 2-31
costs, in United States, 2-2
historical developments in twentieth century, 1-7–1-11
rates, 1-8–1-9
public psychiatry changes and, 1-9–1-10
social factors in, 1-9
Individualized educational plan (IEP), 13-8
Individuals with Disabilities in Education Act (IDEA), 13-8
Inhalants
intoxication
signs/symptoms, 5-32–5-33
treatment of, 5-32
use at time of offense, 5-4
withdrawal, 5-32
Inmates
adaptation, signs of, 2-23
bullying, 2-27–2-28
classification of, 2-6
code of, 2-21–2-22
con games, 2-19
counts of, 2-6
deprivation of material possessions, 2-20–2-21
drug use at time of offense, 5-4
gang membership of, 2-24
hierarchy of, 2-24–2-26
initiation rituals for, 2-24–2-25
isolation of, 2-20–2-21
“lifers,” 2-26
population
demographics, 1-9
mental illness prevalence in, 10-1
substance abuse prevalence in, 10-1–10-2
protective custody of, 2-7
psychological difficulties/problems of, 2-22–2-23
respect, by other inmates, 2-25
return to society, 2-22
searches of, 2-6
segregation of, 2-7–2-8
socialization into prison life, 2-21–2-24
toughness of, 2-25
transportation outside facility, 2-6
Insanity defense, 10-8, 10-10
Insomnia
assessment of, 4-2–4-5
incidence/prevalence of, 9-3–9-4
mood disorders and, 4-4
prevalence of, 4-1–4-2
primary, 4-2
daytime sleepiness and, 4-4
diagnostic criteria for, 4-9
environmental factors and, 4-3
pathogenesis of, 4-2–4-3
situational factors and, 4-3
treatment of, 4-3–4-4
Institute of Behavioral Research (IBR), 12-24
Institutional review boards (IRBs), 20-5
Intellectually disabled offenders, 14-1–14-18
adaptation to incarceration, 4-14–14-15
autistic spectrum disorders in, 14-15–14-16
characteristics of, 14-7–14-9
age, 14-8
IQ, 14-8
prior exposure to violence, 14-8
psychiatric problems, 14-8–14-9
sexual offenses, 14-9
socioeconomic status, 14-8
unemployment, 14-9
competency of, 14-7
criminal behavior and, 14-3–14-4
comorbid antisocial personality disorder and, 14-4
prevalence of, 14-3–14-4
diversion programs, 14-11—14-13
dual diagnosis, 14-10–14-11
epidemiology, in criminal justice system, 14-6
fetal alcohol syndrome and, 14-16–14-17
Joint Commission on Accreditation of Health Care Organizations (JCAHO), 12-11
Jurisdictions, hierarchy of, 3-4
Juvenile offenders, 13-1–13-24
in adult facilities
blended sentencing and, 13-7
demographic information, 13-2–13-4
mental health information, 13-4–13-6
number of, 13-2, 13-6
offenses of, 13-3
problems with, 13-7–13-8
transfer or waiver, determination of, 13-6–13-7
anxiety disorders, 13-16–13-18
with attention deficit hyperactivity disorder, 13-12–13-14
autistic spectrum disorders and, 14-16
with conduct disorder
with ADHD, 13-9
assessment of, 13-9–13-10
diagnosis of, 13-9
prevalence rates, 13-9
prognosis for, 13-9
mental health assessments, 13-8–13-9
mood disorders, 13-18–13-21
with psychotic disorders, 13-21–13-24
with substance use disorders, 13-14–13-16

K
Ketamine
intoxication, 5-30–5-31
withdrawal, 5-31

L
Labeling theory, 1-10
Latino women, incarcerated, 15-2
Laws, governing psychiatrists, 3-3–3-9
Legal situation, of inmate, effect of malingering on, 9-3
Leuprolide, for sex offender treatment, 17-17–17-18
Level of Care Utilization System (LOCUS), 12-23–12-24
Leydig cells, 17-14–17-15
LHRH agonists (luteinizing hormone releasing hormone analogues), 17-17–17-18
Liability management, 3-1–3-22
case law principles, 3-9–3-11
clinical ramifications of law, 3-14–3-19
correctional institution issues, 3-20–3-21
criminal justice system issues, 3-20–3-21
laws under which psychiatrist operates,
3-3–3-9
risk, appropriate documentation and,
3-15
statutes and standards, 3-11–3-14
tort-based standards, 3-13
Linear layout, for correctional facility,
2-15–2-16
Lithium
FDA approval of, 1-10
hypothyroidism from, 15-13
for juvenile bipolar disorder, 13-21
Local law, regulating correctional practice,
3-13–3-14
Lockdown, 2-6
LOCUS. See Level of Care Utilization
System
Lofexidine, for opioid withdrawal, 5-19
Long-term segregation (LTS), 18-4
Lorazepam, for alcohol withdrawal
treatment, 5-12
LSD intoxication, 5-27–5-28
LTS. See Long-term segregation
Luteinizing hormone releasing hormone
analogues (LHRH agonists),
17-17–17-18
M
MacArthur Community Violence Study,
12-15–12-16
Major depressive disorder
hunger strikes and, 8-9–8-10
insomnia and, 4-4
prevalence of, 8-9
symptoms of, 8-9
Malingering, 9-1–9-11
antisocial personality disorder and,
9-6–9-7
anxiety and, 9-7
confrontation to “save face,” 9-10
definition of, 9-1–9-2
detection of, 9-7–9-9
baseline of suspicion for, 9-7–9-8
criteria for, 9-8–9-9
greater exposure and, 9-9
vs. factitious disorder, 9-5
false imputation, 9-4–9-5
vs. Ganser’s syndrome, 9-5–9-6
motives for, 9-2–9-4
primary gain, 9-2
secondary gain, 9-3
partial, 9-4
psychological tests for, 9-9–9-10
pure, 9-4
Malpractice, 3-13
“Manipulative behavior,” suicide risk and,
6-5
“Manipulator” label, 3-20
MAO. See Monoamine oxidase, alcoholism
and
MAO-A gene polymorphisms, alcoholism
and, 10-13
Marijuana (cannabis)
acute intoxication
adverse reactions, 5-26
symptoms of, 5-24–5-26
treatment of, 5-26
overdose, 5-26
premorbid schizophrenia and, 10-8
prevalence of use, 5-24
use at time of offense, 5-4
withdrawal, 5-26–5-27
Massachusetts, Forensic Transition Team,
15-17
Massachusetts Youth Screening
Instrument–Second Version (MAYSI-II),
13-5
Maximizing Opportunities for Mothers to
Succeed (MOMS), 15-18
MAYSI-II. See Massachusetts Youth
Screening Instrument–Second Version
McLean asylum, 1-5
MDMA
(3,4-methylenedioxymethamphetamine;
Ecstasy), 10-6
Media coverage, of inmate problems, 3-5
Medicaid, 12-29, App.-6
Medical care
assessment
for incarcerated women, 15-9–15-10
for reentry program, 12-22
decision making capacity, assessing
during hunger strike, 8-7–8-8
during hunger strike, 8-6–8-7
inmate treatment rights and, 3-6–3-7
necessities, vs. psychological/psychiatric
necessities, 10-16
for psychiatric diagnoses, 8-8
right to accept or reject, 8-3
Medical conditions, sleep disorders and, 4-5
Medical ethics, confidentiality, correctional modifications of, 19-4
Medical records, relevant information for, 3-15–3-16
Medical units, in correctional facility, 2-15
Medicare, 12-29
Medication
See also specific medications
continuity in reentry transition, 12-28
obligation to provide, 12-12
prescriptions, manipulative inmates and, 11-6
Medroxyprogesterone acetate (MPA), 14-14, 17-16
Megaprisons, 1-9
Men, with comorbid substance abuse, 12-15–12-16
Mental capacity assessment, during hunger strike, 8-7–8-8
Mental health care
assessments
for incarcerated women, 15-8–15-11
for juvenile offenders, 13-8–13-9
for comorbidity, 10-14
evaluations
preplacement, for administrative segregation, 19-7
in segregated housing, 18-9–18-11
issues, in segregated housing, 18-3–18-4
levels, in segregated housing, 18-11–18-17
behavioral incentive programs, 18-15–18-16
case management, 18-13–18-14
crisis intervention, 18-12–18-13
day treatment, 18-14–18-15
enhanced outpatient programs, 18-14–18-15
inpatient acute and intermediate care, 18-16–18-17
interdisciplinary treatment teams, 18-12
“walk-in,” 18-12–18-13
minimally adequate, 3-7
prevention, for incarcerated women, 15-7–15-8
services, 12-5
treatment barriers, overcoming in segregated housing, 18-4–18-7
treatment programs, minimally adequate, criteria for, 1-10–1-11
Mental health professionals
con games, inmate, 2-19
in correctional facility, 2-15
denial of fear of inmates, 11-5
fear of inmates, 11-5
practice, state laws governing, 3-12–3-13
Mental illness
in eighteenth and nineteenth century
America, 1-4–1-7
incarceration for, 1-1–1-2
prevalence
in inmate population, 10-1
in juvenile offenders, 13-4–13-5
prevalence, in intellectually disabled population, 14-10–14-11
prevalence in prison population, 1-11–1-12
psychiatric diagnoses. See Psychiatric diagnoses; specific psychiatric disorders
segregation/housing for, 1-4–1-7
Mental retardation
See also Intellectually disabled offenders
fetal alcohol exposure and, 14-2
Meperidine. See Opioids
Meprobamate, 5-16
Methadone
maintenance in jail, 5-20
for opioid detoxification, 5-18–5-19
Methamphetamines
chronic use, psychosis, 10-3
increased usage of, 5-20
neurotransmitters and, 10-11
psychosis from, 10-9–10-12
relapse, 10-11–10-12
single positron emission computed tomography (SPECT), 10-11
withdrawal, 15-13
Miller Forensic Assessment of Symptoms Test (M-FAST), 9-9–9-10
Mindfulness skills, 7-20
Mini International Neuropsychiatric Interview (MINI), 12-21, 20-8
Minnesota Multiphasic Personality Inventory-2 (MMPI-2), 9-6–9-7, 9-10
Minnesota Sex Offender Screening Tool–Revised (MnSOST-R), 17-9
Minority women, personality disorders and, 15-7
Mirtazapine, 8-11, 13-21, 16-6
Mission Matters (Seay and Vladeck), 12-6
INDEX

[References are to pages.]

MMPI-2. See Minnesota Multiphasic Personality Inventory-2
MnSOST-R. See Minnesota Sex Offender Screening Tool-Revised
Modified therapeutic community (MTC), 10-14
MOMS. See Maximizing Opportunities for Mothers to Succeed
Monoamine oxidase (MAO), alcoholism and, 10-13
Mood disorders (affective disorders)
insomnia and, 4-4
of juvenile offenders, 13-18–13-21
assessment of, 13-19–13-20
prevalence of, 13-18–13-19
treatment of, 13-20–13-21
types of, 13-18–13-19
juvenile offenders and, 13-5
Mood stabilizers
for conduct disorder, 13-11
for juvenile bipolar disorder, 13-21
liver toxicity, 15-14
Moral treatment, 1-5
Morphine. See Opioids
MPA. See Medroxyprogesterone acetate
MST. See Multisystemic therapy, for conduct disorder
MTC. See Modified therapeutic community
Muhammad, John Allen, 8-2
Multi-dimensional Scale of Perceived Social Support, 15-10
Multisystemic therapy (MST), for conduct disorder, 13-11–13-12
Murderers, in inmate hierarchy, 2-25–2-26
Murder rate, by women, 15-3

N
Naloxone, for opioid overdose, 5-18
NAMI. See National Alliance on Mental Illness
Narcissism, countertransference and, 11-9
National Alliance on Mental Illness (NAMI), App.-3
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 20-4
National Commission on Correctional Health Care (NCCHC), 19-8, App.-4
professional standards, 12-11–12-12
Standards for Health Services in Prisons, 3-9–3-11
National Drug Research Institute (NDRI), 12-21
National GAINS Center, 12-7, App.-3–App.-4
National Institute for Drug Abuse (NIDA), 12-21
National Institutes of Health, 20-9
National Mental Health Association (NMHA), App.-4
National Research Act of 1974, 20-4
Nausea/vomiting, CIWA-Ar scale, 5-9
NCCHC. See National Commission on Correctional Health Care
Negligence
local laws, 3-13
state laws, 3-13
Neuroimaging, in prisoner research, 20-7
Neurotransmitters, methamphetamine and, 10-11
New Freedom Commission, 12-15
Newjack: Guarding Sing Sing (Conover), 2-27
New York-Auburn Plan of 1819, 1-3
New York City, reentry program, 12-15
NIDA. See National Institute for Drug Abuse
NMDA. See N-methyl-D-aspartic acid
NMHA. See National Mental Health Association
No malfeasance, traditional medical ethics and, 19-2
Nonpharmacological treatment, for psychiatric diagnoses, 8-8
Notifications, of suicide attempt, 6-15
Nucleus accumbens, inhibitory G protein levels in, 10-9
Nuremberg Code, 20-3

O
Obsessive-compulsive disorder (OCD), of juvenile offenders, 13-17
Office for Human Research Protection (OHRP), 20-4
Olanzapine
for agitation, 16-8
for juvenile bipolar disorder, 13-21
Opioids (opiates; opium)
overdose, treatment of, 5-18
substance-induced sleep disorders and, 4-5
toxicity, symptoms of, 5-17–5-18
use at time of offense, 5-4
Opioids (opiates; opium) (continued)
withdrawal
complications from, 5-19–5-20
diagnostic criteria, 5-18
symptoms of, 5-18–5-19
treatment of, 5-19
Organic delusional disorder, 12-12
Orientation/clouding of sensorium,
CIWA-Ar scale, 5-11
Orthostatic hypotension, 8-7
Overcrowding, of prisons, 2-17–2-18
Oxazepam, for alcohol withdrawal treatment, 5-12
Oxycodone. See Opioids

P
"Pains of imprisonment” theory, 2-22
Pain syndrome, chronic, sleep disorders and, 4-5
Pankhurst, Emmeline, 8-2
PAQ. See Prison Adjustment Questionnaire
Paranoia, 10-9
Paraphilias, 17-4
Parens patriae, 8-3
Parole
definition of, 2-13
description of, App.-6
historical development of, 1-3
Parole evaluations, 19-8–19-9
Paroxysmal sweats, CIWA-Ar scale, 5-9
PCL. See Psychopathy Checklist
PCL-R. See Psychopathy Checklist–Revised
PCP. See Phencyclidine
Pedophilia
classification
by degree of “sexual fixation,” 17-3
by FBI, 17-3
definition of, 17-4
paraphilias, 17-4
Peer-support programs, for incarcerated women, 15-16
Penile plethysmography, 17-10
Pennsylvania Plan of 1790, 1-3
Perphenazine, 16-8
Personality Assessment Inventory, 9-6
Personality disorders
Cluster A, 15-7
Cluster B, 15-7
hunger strikes and, 8-11–8-12
incarcerated women and, 15-7
severe, management of, 20-8–20-9
Personnel. See Staff
Phallometry, 17-10
Pharmacotherapy
See also specific medications
for anxiety, in women, 15-12–15-13
assessment for medication, 15-11–15-12
for bipolar disorder, 15-13–15-14
for cognitive disorders, 16-7–16-8
for depressive disorders, 16-5–16-6
broad-spectrum antidepressants, 16-6
SSRIs, 16-5–16-6
tricyclic antidepressants, 16-5
in women, 15-12–15-13
for incarcerated women, 15-11–15-14
for juvenile offenders, 13-9
selection of medication, 15-12
for sex offenders, 17-13–17-19
antiandrogens and hormonal agents,
17-15–17-18
modulation of hypothalamic-pituitary
gonadal axis, 17-14–17-15
in prison setting, 17-18–17-19
selective serotonin reuptake inhibitors,
17-14
for suicide risk management, 6-7–6-8
Phencyclidine (PCP)
intoxication
acute, treatment of, 5-31
signs/symptoms of, 5-29–5-31
toxicity, 5-31
withdrawal, 5-31
Phenobarbital, for alcohol withdrawal treatment, 5-13
Phenothiazines
for alcohol withdrawal treatment, 5-13
contraindications, 5-23
Phenytoin, for seizure prevention in alcohol withdrawal, 5-15
Physical examinations, in substance use disorder screening, 5-4–5-5
Physicians. See also Psychiatrists
boredom, in dealing with narcissistic patient, 11-9
clinical judgment of, 3-20
countertransference reactions, to sex offenders, 11-9–11-10
guiding principles for, 3-21–3-22
relationship with patients. See Doctor–patient relationship
second opinion for suicide risk assessment, 6-6
working in segregation housing
development of clinical rapport,
18-6–18-7
training for, 18-6
Political policy
incarceration of mentally ill and, 20-10
rising prison population and, 10-2
Polygraphy, 17-10
Posttraumatic stress disorder (PTSD)
incarcerated women and, 15-6
HIV and, 15-6–15-7
of juvenile offenders, 13-17
psychotherapy for, 15-15
selective serotonin reuptake inhibitors for
women, 15-12–15-13
substance abuse in women and, 15-16
Pregnancy
with depression, treatment for, 15-13
incarcerated women and, 15-4–15-5
screen, for incarcerated women, 15-10
Primary gain, from malingering, 9-2
Prison Adjustment Questionnaire (PAQ),
15-11
Prison institutional reform litigation,
monetary damages, 3-2
Prisonization, 2-20–2-24
Prison Litigation Reform Act of 1995, 3-2
Prison Rape Elimination Act, 2-29–2-30
Prisons
challenges for, 1-13
classifications of, 2-10–2-13
intermediate care units, 2-12–2-13
maximum security, 2-10–2-11
medium security, 2-10
minimum security, 2-10
supermax custody, 2-11–2-12
culture of, 2-20–2-31
fixed adolescence and, 2-26–2-28
prisonization, 2-20–2-24
current status of, 1-11–1-13
definition of, 2-9–2-10
as “failed social-political experiments;”
2-31
gang membership, 2-24
historical development of, in early years,
1-2–1-3
vs. jails, 2-8–2-9
medical treatment in, 1-10
mental health treatment, requirements for,
18-2–18-3
overcrowding of, 2-17–2-18
population
demographics, women, 15-2–15-5
elderly inmates, prevalence of, 16-1
growth in, political agendas and, 10-2
mental health problems in, 10-2
with comorbid substance abuse
disorders, 10-2
risk factors, for suicide, 6-2–6-3
privatized, 1-12–1-13
psychiatric treatment in, 1-10
recidivism and, 2-4
reforms, in later nineteenth century, 1-3
reforms/improvements for, 2-31–2-32
Stanford Prison Experiment, 2-27–2-28
transitions from, for women inmates,
15-17–15-18
violence in, 2-29–2-31
Privatized detention centers, 1-12–1-13
Probation
definition of, 2-13
description of, App.-6–App.-7
Problem-solving skills, 7-20
Professional judgment rule, 3-10–3-11
Professional standards
evolution of continuum of care for
reentry and, 12-11–12-12
local regulations, 3-13–3-14
“Pros and cons” strategy, in dealing with
self-injurious behavior, 7-11–7-12
Prostitution, 15-4
Protective custody, 2-7
Psychiatric assessment, of intellectually
disabled offenders, 4-13–14-14
Psychiatric diagnoses
See also specific psychiatric disorders
discrimination against, 3-11–3-12
feigning. See Malingering
geriatric, common, 16-3–16-9
in hunger strikes, 8-8–8-12
eating disorders, 8-11
general treatment principles for,
8-8–8-9
major depressive disorder, 8-9–8-10
personality disorders, 8-11–8-12
psychoses, 8-10–8-11
of incarcerated women, 15-5–15-7
related to chemical dependence
conditions associated with substance
use, 10-12–10-14
substance-related disorders in
DSM-IV-TR, 10-3–10-12
Psychiatric diagnoses (continued)
  secondary to chemical dependence, 10-1–10-18
  assessment issues, 10-14–10-15
  treatment issues, 10-15–10-17
Psychiatric genetics research, 20-7
Psychiatrists
  countertransference reactions. See Countertransference
evaluation, for death row inmates, 19-9
  mitigating factors, for disciplinary process, 19-6–19-7
  treatment rights, for inmates, 10-8–10-9
Psychiatric genetics research, 20-7
Psychiatric genetics research, 20-7
Psychiatrists
  clinical ramifications of laws, 3-14–3-19
  Americans with Disabilities Act, 3-11–3-12
  documentation, 3-14–3-16
  fostering of consistency of care, 3-13
  local, 3-13–3-14
  state, 3-12–3-13
  suicidality/suicide risk, 3-16–3-19
documentation by, 3-14–3-16
dual agency of, 19-1–19-2
  definition of, 19-3
  potential conflict and, 19-3–19-4
  federal constitutional standards, 3-2–3-3
  deliberate indifference, 3-6
everal cases and, 3-5–3-6
  Gamble standard, 3-6–3-8
  historical development of, 3-3–3-5
guiding principles from case law, 3-9–3-11
  information sources for, 3-21
inmate competency assessment for
disciplinary hearing, 19-5–19-6
  inmate disciplinary process and, 19-5–19-7
  non-pertinent information and, 3-20
  optimal functioning in correctional system, 3-21
  parole evaluations, 19-8–19-9
  pressures/influences on, 3-21
  role in hunger strikes, 8-5–8-8
  in reentry planning, 12-17
  in sex offender treatment, 17-13
  Psychiatrists’ Risk Management Program, 3-16
Psychological effects, of solitary confinement, 2-7–2-8
Psychological factors, in alcohol withdrawal, 5-16
Psychological tests, for malingering, 9-9–9-10
Psychopathic Personality Inventory, 9-6
Psychopathology, suicide risk and, 6-4
Psychopathy Checklist (PCL), 15-7
Psychopathy Checklist–Revised (PCL-R), 10-13–10-14
Psychosocial issues, assessment, for reentry program, 12-22
Psychostimulants. See Stimulants
Psychotherapy
  for incarcerated women, 15-14–15-15
  outcomes research, 20-8
  for sex offenders, 17-12
  for suicide risk management, 6-7–6-8
Psychotic disorders, 8-10–8-11
  See also Schizophrenia
  alcohol-induced, 5-14
  amphetamine, 10-9–10-12
  from chronic methamphetamine use, 10-3
  in geriatric inmates, 16-8–16-9
  hunger strikes and, 8-10–8-11
  in intellectually disabled population, 14-10–14-11
  of juvenile offenders, 13-21–13-24
  assessment of, 13-22–13-23
  etiology of, 13-22–13-23
  prevalence of, 13-21–13-24
  substance use and, 13-22
  treatment of, 13-23–13-24
  marijuana-induced, 5-26
  methamphetamine, 10-9–10-12
  prevalence of, 8-10
  stimulant-induced, 5-20–5-21
  substance-induced, 10-7–10-9
  symptom classification, 10-8
  symptoms of, 8-10
  transient vs. prolonged, 10-9
Psychotropics
  for agitation in intellectually disabled offenders, 14-14
deinstitutionalization and, 1-10
twenty-four-hour psychiatric care and, 1-12
PTSD. See Posttraumatic stress disorder
Public health, incarceration of mentally ill and, 20-10
Public-interest legal services, 3-5
Public safety, reentry programs and, 12-15–12-16
Punishment
desire, of clinician, 11-7
theories of, 2-3–2-5

Q
Quetiapine, for juvenile bipolar disorder, 13-21

R
Race, of juvenile offenders, 13-5–13-6
Rape, prison, 2-29
Rapid Risk Assessment for Sexual Offense Recidivism (RRASOR), 17-8–17-9
Rapists, classification by FBI, 17-3
Recidivism
intellectually disabled offenders and, 14-10
mental illness with chemical dependence and, 10-2
rates, 1-9
from 1950–1965, 1-7
for women inmates, 15-16
reduction, substance-related disorder treatment programs and, 10-15
risk factors, 12-3–12-4
sexual
psychiatric factors in, 17-13
risk factors for, 17-5–17-8
Recordkeeping, constitutional care and, 3-9
Reentry programs, 12-1–12-32
ability to pay for services and, 12-29
APIC model, 12-7
arrest and release rates, 12-3
availability of correctional assessment and treatment, 12-4–12-6
challenges, for women offenders, 15-18
continuum of care, 12-31
creation of, 12-16–12-25, 12-31–12-32
assessing community resources for, 12-17–12-18
assessment instruments for, 12-23–12-24
assessment domains, 12-21–12-23
collaborative stakeholder consensus building resources for, 12-18–12-19
screening instruments for, 12-19–12-21
criminal justice services linkage models, 12-8–12-9
developmental evolution of availability of correctional programs and, 12-4
comorbidity and, 12-4
recidivism reduction and, 12-4–12-5
evolution of continuum of care, 12-9–12-14
fledging litigation and, 12-12–12-14
personal vignette, 12-9–12-10
professional standards and, 12-11–12-12
financial benefit of, 12-14–12-15
funding mechanisms, 12-19
implementation
basic parameters for, 12-25–12-26
community mental health services and, 12-27
correctional system and, 12-27
environment for, 12-27–12-29
identifying population for, 12-27
institutional-cultural perspective, 12-26
population make-up, review of, 12-26–12-27
for incarcerated women, 15-16–15-19
initial, tracking of, 12-29–12-30
medication continuity and, 12-24–12-25
models, 12-8
planning, 12-6–12-8
historical lack of interest in, 12-6–12-7
increased awareness in, 12-7–12-8
role of psychiatrist in, 12-17
public safety and, 12-15–12-16
research, 12-8–12-9
Serious and Violent Offender Reentry Initiative, 12-9
Refeeding, after hunger strike, 8-7
Rehabilitation
as incarceration goal, 10-16
punishment and, 2-3–2-4
restraint and, 2-4
after World War II, 1-7
Rehabilitation Act of 1974, Section 504, 3-11
Relaxation technique, 4-10–4-11
Release rates, 12-3
Remote surveillance layout, for correctional facility, 2-16
Research, prisoner, 20-1–20-10
ethics, current guidelines and, 20-2–20-5
funding for, 20-5
history of, 20-1–20-2, 20-3
on intellectually disabled offenders, 14-2–14-3
investigational drug trials, 20-1–20-2
with mental illness
clinical, 20-7–20-9
pragmatics of, 20-5–20-6
preclinical, 20-6–20-7
need for, 20-2
translational, 20-9–20-10
Residential treatment units (RTUs), 2-12–2-13
Respect for persons, forensic ethics and, 19-3
Restraint
definition of, 2-4
rehabilitation and, 2-4
Retribution, definition of, 2-4
Reynolds Adolescent Depression Scale, 13-20
Rights
of criminal delinquents, 1-1
of inmates, basic, 3-9
to treatment, 10-15
Riots, inmate, 2-30–2-31
Risk assessment/management assessment,
for reentry program, 12-22–12-23
Risperidone, 16-8
RRASOR. See Rapid Risk Assessment for Sexual Offense Recidivism
RTUs. See Residential treatment units
Rush, Benjamin, 1-4
S
“Sallyport,” 2-14
Sands, Bobby, 8-2
Schizoaffective disorder, 10-8
Schizophrenia
amphetamine model of, 10-9
antipsychotic medications for juvenile offenders with psychotic behavior, 13-23–13-24
anxiety and, 9-7
dopamine system abnormalities and, 10-9
incarcerated women and, 15-6
in-house tattooing and, 2-24
insomnia and, 4-4
negative symptoms, in chronic methamphetamine use, 10-10
negative symptoms of, 10-9
premorbid, cannabis and, 10-8
symptoms, amphetamine psychosis symptoms and, 10-10
Schizotypal disorder, 10-8
SCID. See Structured Clinical Interview for Diagnosing DSM-IV Disorders
Screening
instruments
for juvenile offenders, 13-8
for reentry programs, 12-19–12-21
for pregnancy, in incarcerated women, 15-10
in segregated housing, 18-9–18-11
Searches, of inmates, 2-6
Secondary gain
from malingering, 9-3–9-4
potential, diagnostic acuity and, 11-6
Secure housing units, 2-7
Security personnel, limited disclosure to, 19-4–19-5
Security precautions, in segregation housing, mental health treatment and, 18-5–18-6
Sedative hypnotics
intoxication, 5-16
short-acting, intoxication, 5-16
substance-induced sleep disorders and, 4-5
withdrawal, 5-16–5-17
Seeking Safety, 15-15
Segregated housing, 8-1–18-18
administrative. See Administrative segregation
disciplinary, 2-7–2-8
historical aspects of, 18-1–18-2
history of, for mentally ill individuals, 1-4–1-7
inmate population in, 18-3–18-4
levels of mental health care in, 18-11–18-17
behavioral incentive programs, 18-15–18-16
case management, 18-13–18-14
crisis intervention, 18-12–18-13
day treatment, 18-14–18-15
enhanced outpatient programs, 18-14–18-15
inpatient acute and intermediate care, 18-16–18-17
interdisciplinary treatment teams, 18-12
“walk-in,” 18-12–18-13
maximum-security unit, 18-11
mental health issues
access to care, 18-3
population growth and, 18-3–18-4
risk factors in, 18-7–18-11
mental health treatment
appropriate setting for, 18-5
development of clinical rapport, 18-6–18-7
overcoming barriers to, 18-4–18-7
security precautions and, 18-5–18-6
setting appropriate controls for, 18-7
orientation to, 18-8–18-9
personnel factors, 18-17–18-18
privileges in, 18-15–18-16
reasons for, 18-4, 18-6
screening and mental health evaluation in, 18-9–18-11
security personnel, limited disclosure to, 19-4–19-5
stressors from, 18-8–18-9
types of, 18-4
Seizures
in alcohol withdrawal, 5-14–5-15
in intellectually disabled offenders, 4-13
from opioid withdrawal or intoxication, 5-19–5-20
Selective serotonin reuptake inhibitors (SSRIs)
for anxiety, in women, 15-12–15-13
for depression
in geriatric patients, 16-5–16-6
in women, 15-12–15-13
off-label prescribing, 13-18
for PTSD, in women, 15-12–15-13
for sex offender treatment, 17-14
suicide risk from, 13-21
Self-fulfilling prophecy, 1-10
Self-injurious behavior (SIB), 7-2–7-21
assessments, for incarcerated women, 15-8–15-9
behavioral chain analysis. See Behavioral chain analysis
forms of, 15-9
future, evaluating risk for, 7-20–7-21
operant, appropriate responses to, 7-18–7-19
prevalence, 7-2
prevention
recognizing behavioral continuum, 7-3–7-4
staffing implications for, 7-2–7-3
procedures following, 7-12–7-20
clinical hypothesis formation, 7-16–7-17
controlling variables, assessment of, 7-14–7-16
developing replacement behaviors, 7-19–7-20
disciplinary consequences, 7-13
targeting controlling variables, 7-17–7-18
twenty-four-hour rule, 7-12–7-14
screening instruments, limits of, 7-4–7-5
treatment, 7-5–7-12
general procedures, 7-6–7-8
motivation/engagement strategies, 7-11–7-12
precrisis planning procedures, 7-8–7-10
therapeutic maintenance procedures, 7-10–7-11
Self-report measures
for adolescent substance abuse, 13-15
for anxiety disorders, 13-18
for conduct disorder symptoms, 13-9
Sensory deprivation, in solitary confinement, 2-7–2-8
Serious and Violent Offender Reentry Initiative, 12-9
Sertraline, 13-18
Settled insanity, 10-8, 10-10
Sex offenders, 17-1–17-19
actuarial instruments
MnSOST-R, 17-9
reliability of, 17-8
RRASOR, 17-8–17-9
Static-99, 17-9
classification
heterogeneity of, 17-2–17-3
typologies of, 17-3–17-4
clinicians, clinical vs. forensic duties of, 17-19
countertransference reactions and, 11-9–11-10
ethics, clinical vs. forensic duties, 17-19
identification of sexual predation in, 14-5
in inmate hierarchy and, 2-26
intellectually disabled, 14-9–14-10
Sex offenders (continued)
management of, 17-2
paraphilias, definition of, 17-4
pedophiles. See Pedophiles
psychophysiological assessment, 17-9–17-10
rapists. See Rapists
recidivism risk, risk factors correlated with, 17-5–17-8
risk
assessment of, 17-2, 17-4–17-10
static vs. dynamic factors, 17-5
risk management strategies, 17-5, 17-10–17-11
treatment, 17-11–17-19
environment of care, 17-11–17-12
pharmacological, 17-13–17-19
psychiatrist’s role in, 17-13
psychotherapeutic approaches, 17-12
Sexual abuse, of women inmates, 15-11
Sexual deviancy, in predicting sexual recidivism, 17-6, 17-7
Sexual harassment, of incarcerated women, 15-11
Sexually transmitted disease (STD), incarcerated women and, 15-9–15-10
Sexual masochism, 17-4
See also Paraphilias
Sexual offenses, by intellectually disabled offenders, 14-13
Sexual predator statutes, 17-11
Sexual sadism, 17-4. See also Paraphilias
Shock incarceration, 2-14
Short Drug Abuse Screening Test, 15-6
SHU syndrome, 2-11–2-12
SIB. See Self-injurious behavior
Single positron emission computed tomography (SPECT), of methamphetamine users, 10-11
SIRS, 9-10
Situational factors, in primary insomnia, 4-3
“Skinners,” 2-26
See also Sex offenders
Sleep, promotion, tips/techniques for, 4-10
Sleep disorders, 4-1–4-7
with comorbid mental disorder, 4-4
general medical conditions and, 4-5
insomnia. See Insomnia
substance-induced, 4-5
 treatment, 4-5–4-7
  nonpharmacological, 4-6
  pharmacological, 4-6–4-7
Sleep hygiene education, 4-6
Social Security benefits, 12-29
Social skills training, for intellectually disabled offenders, 14-12–14-13
Social support, for incarcerated women, 15-10
Socioeconomic status, of incarcerated women, 15-2–15-3
Solitary confinement, 2-7–2-8
SPECT (single positron emission computed tomography), of methamphetamine users, 10-11
“Sporks,” plastic, 6-7
SSI. See Supplemental Security Income
SSRIs. See Selective serotonin reuptake inhibitors
Staff
chain of command for, 2-19
civilians, 2-18–2-19
correctional officers. See Correctional officers
malignant attitudes of, 2-19–2-20
perceptions of inmate behavior, 14-5
reactions to inmate self-injurious behavior, 7-18–7-19
preventive measures, 7-2–7-3
tolerating “being fooled,” 7-4
security personnel, limited disclosure to, 19-4–19-5
for segregated housing, 18-17–18-18
shortages, 2-20
unit managers, 2-19
Stanford Prison Experiment, 2-27–2-28
Starvation, medical effects of, 8-6–8-7
State laws
community standards of practice, 3-13
governing mental health practice, 3-12–3-13
variations in, 3-13
Static-99, 17-9
Status epilepticus, in alcohol withdrawal, 5-15
STDs. See Sexually transmitted disease, incarcerated women and
Stimulants
for ADHD, 13-13–13-14
intoxication, 5-20–5-21
physiological effects of, 5-21–5-22
symptoms of, 5-21–5-22
overdose
effects of, 5-24–5-25
treatment of, 5-21, 5-23
use at time of offense, 5-4
withdrawal
diagnostic criteria, 5-23
symptoms of, 5-23
Stress, “circle of,” 2-20
Stress-vulnerability-coping model, cannabis and, 10-8
Structured Clinical Interview, for DSM-III-R, 15-7
Structured Clinical Interview for Diagnosing DSM-IV Disorders (SCID), 20-8
Structured Interview of Reported Symptoms (SIRS), 9-6
Structured Inventory of Malingering Symptomatology, 9-6
Subpart C, 20-4–20-6, 20-9
Substance-induced disorders, 10-4–10-12
amnestic disorder, substance-induced persisting, 10-5–10-6
dementia, substance-induced persisting, 10-4–10-5
methamphetamine psychosis, 10-9–10-12
mood disorder, substance-induced persisting, 10-6–10-7
psychotic disorder, substance-induced, 10-7–10-9
sleep disorders, 4-5
Substance-related disorders, in DSM-IV-TR, 10-3–10-12
substance-induced disorders. See Substance-induced disorders
substance use disorders. See Substance use disorders
Substance use disorders
abuse
age and, 16-1
vs. dependence, 10-3–10-4
intoxication vs. withdrawal, 5-3
prevalence, in inmate population, 10-1–10-2
psychiatric symptoms from, 10-3
vs. substance dependence, 10-3–10-4
suicide risk and, 6-6
treatment, for incarcerated women, 15-15–15-16
treatment rights, for inmates, 10-8–10-9
arrest rates and, 12-3
with comorbid disorders, incarcerated women and, 15-6
conditions associated with antisocial behavior and psychopathy, 10-13–10-14
dual diagnosis, 10-12–10-13
in correctional populations, prevalence, 5-3–5-4
dependence vs. abuse, 10-3–10-4
incarcerated women and, 15-5–15-6
of juvenile offenders, 13-5, 13-14–13-16
assessment of, 13-15
prevalence of, 13-14
risky behavior and, 13-14–13-15
treatment of, 13-16
screening for, 5-4–5-5
substance dependence vs. substance abuse, 10-3–10-4
treatment, 1-9
treatment referral, 5-6
Suffragettes, hunger strike by, 8-2
Suicide/suicidality, 6-1–6-10
aftermath, dealing with, 6-9–6-10
assessment progress notes, 3-18–3-19
attempts
notifications of, 6-15
prevention, staffing implications for, 7-2–7-3
sample policy, 6-15
communication and, 7-7
contracts, 7-7
correctional facility antisuicide architecture and, 2-16–2-17
deterrents, 6-5
forseeability, 3-18
hunger strikes and, 8-12
ideation, 6-4
incidence/prevalence of, 6-1–6-2
methods, 6-5
past attempts, factors associated with, 15-9
prevention, documentation and, 3-17–3-18
rates, 7-2
in correctional facilities, 3-17
in jail vs. community, 15-8–15-9
in juvenile custodial settings, 7-2
risk assessment, 6-3–6-6
checklist, 6-12–6-13
coexisting psychopathology and, 6-4
Suicide/suicidality, risk assessment (continued)
- current situational context and, 6-4
- documentation, 6-6
- future perspective and, 6-5
- history of attempts and, 6-4–6-5
- impact of interview, 6-6
- intoxication and, 6-6
- “manipulative behavior” and, 6-5
- rating scales for, 6-3
- research on, 20-8
- second opinions, 6-6
- “suicidal gesture” and, 6-5
- risk factors
  - antidepressants and, 13-20
  - isolation and, 3-17
  - mismanagement of, 3-16–3-17
  - from solitary confinement, 2-8
  - substance abuse/dependence and, 5-5
- risk management, 6-7–6-9
  - APA guidelines, 6-8–6-9
  - functions of, 6-7
  - institutional protocol for, 6-7
  - observation status, 6-15
  - research on, 20-8
  - sample policy, 6-14–6-15
- Suicide Watch. See Suicide Watch therapeutic response for, 6-7–6-8
- screening instruments, limits of, 7-4–7-5
- self-injurious behavior, behavioral continuum and, 7-2–7-4
- with tricyclic antidepressants, 16-5
- Suicide Watch
  - clothing item removal for, 6-14
  - housing for, 6-14
  - sample policy, 6-14
- Supermax or “maxi-maxi” prisons, 1-8, 2-11–2-12
- Supplemental Security Income (SSI), App.-7
- Symptom-triggered therapy, for alcohol withdrawal, 5-8–5-11, 5-12

T
- Tactile disturbances, CIWA-Ar scale, 5-10
- TANF (Temporary Assistance for Needy Families), App.-7
- Tardive dyskinesia, 16-8
- Task Force for the Correctional Service of Canada, 15-18
- Tattooing, in-house, 2-24

Temporary Assistance for Needy Families (TANF), App.-7
- Test of Memory Malingering (TOMM), 9-10
- Testosterone biosynthesis, rate-limiting step in, 17-14–17-15
- Thiamine deficiency, 10-5
- Thiothixene, 16-8
- Three-strikes law, 1-13
- Tokyo Declaration, 8-3
- TOMM. See Test of Memory Malingering
- Torsades de pointes, 5-18
- Toxicology screens, random urinary, 13-15
- Training of correctional staff, for suicide risk management, 6-9

Transference
- in correctional setting, 11-4
- definition of, 11-2
- repetition/reenactment of experiences and, 11-2
- in therapeutic encounters, 11-2

Transitional services. See Reentry programs

Transitions
- continuity of care for, 12-13–12-14
- from jails, for women inmates, 15-16–15-17
- from prisons, for women inmates, 15-17–15-18

Translational research, on prisoners, 20-9–20-10

Transsexual inmate, rape, deliberate indifference standard and, 3-8

Transvestic fetishism, 17-4
See also Paraphilias

Trauma, assessment of, 12-24

Trauma-related disorders, incarcerated women and, 15-6–15-7

Trauma Symptom Inventory (TSI), 15-15

Trazodone, 4-7, 16-6

Treatment
See also under specific disorders
- constitutional care and, 3-9
- for death row inmates, 19-9
- decisions, documentation of, 3-14–3-15
- modalities, in diversion programs for intellectually disabled offenders, 14-12–14-13
- of psychiatric conditions secondary to chemical dependence, 10-15–10-17
- refusal, by death row inmates, 19-10
- refusal or failure to provide, 10-15
INDEX

[References are to pages.]

to restore competency for execution, 19-9–19-10
of substance use disorders, of juvenile offenders, 13-16
Treatment rights
for substance abuse treatment, 10-8–10-9
for substance-related psychiatric conditions, 10-15–10-17
Tremor, CIWA-Ar scale, 5-9
Tricyclic antidepressants
for ADHD, 13-13
advantages of, 16-5
for depression, 15-13, 16-5
disadvantages of, 16-5
Trifluoperazine, 16-8
Triptorelin, for sex offender treatment, 17-17–17-18
Trust, clinician’s inability, countertransference and, 11-6–11-7
TSI (Trauma Symptom Inventory), 15-15
Tuke, William, 1-5
Twelve-Step treatment programs, for substance use disorders, of juvenile offenders, 13-16
Twenty-four-hour rule, for self-injurious behavior, 7-12–7-14

U
UI. See Urban Institute
UMs. See Unit managers
Uniform Determinate Sentencing Act of 1976, 1-7
Unit managers (UMs), 2-19
Urban Institute (UI), App.-4
USDHHS (Department of Health and Human Services), 20-5, 20-9

V
Validation, in dealing with self-injurious behavior, 7-11
Valproic acid (valproate)
for bipolar disorder, 5-13, 5-14
for seizure prevention, in alcohol withdrawal, 5-15
teratogenicity, 15-13
Venlafaxine, 13-21, 16-6
Victimization
of juvenile offenders in prison, 13-7–13-8
of mentally ill clients with comorbid substance abuse, 12-16
Violence
inmate-on-inmate, 2-22
in prison, 2-29–2-31
Violent mentally ill clients, with comorbid substance abuse, 12-15–12-16
Visual disturbances, CIWA-Ar scale, 5-10
Voyeurism, 17-4
See also Paraphilias

W
“Walk-in” mental health care, in segregated housing, 18-12–18-13
“War on drugs,” rising prison population and, 10-2
Washington State Department of Social and Health Services, 12-15
Weight loss, from hunger strike, 8-6–8-7
Wernicke-Korsakoff syndrome (WKS), 10-5
Wernicke’s encephalopathy, 5-16, 8-7
Weyer, Johann, 1-4
Withdrawal.
See also under specific drugs vs. intoxication, 5-3
signs/symptoms of, 5-3
WKS. See Wernicke-Korsakoff syndrome
WMT. See Word Memory Test
Women, incarcerated, 15-1–15-19
assessments, 15-8–15-11
medical, 15-9–15-10
for mental health needs, 15-8
pregnancy screen, 15-10
for self-harm behavior, 15-8–15-9
of stressors, 15-10–15-11
with comorbid substance abuse, 12-15
criminal history of, 15-4
demographics, 15-2–15-5
education, 15-2
population growth rate, 15-3
race/ethnicity, 15-2
Socioeconomic status, 15-2–15-3
discharge planning, 15-16–15-19
eating disorders and, 8-11
impact of motherhood on, 15-4
mental health service provision, 15-7–15-8
mothers, parenting issues for, 15-11
offenses, types of, 15-3–15-4
pregnant
risks for, 15-4–15-5
stressors for, 15-11
Women, incarcerated (continued)  
psychiatric diagnoses, 15-5–15-7  
with substance abuse problems  

case management for, 15-17–15-18  
Health Link Program for, 15-17  
treatment, 15-11–15-16  
dialectical behavioral therapy, 15-16  
peer-support programs, 15-16  
pharmacotherapy, 15-11–15-14  
psychotherapy, 15-14–15-15  
for substance abuse, 15-15–15-16  

Women’s Advocacy Project (WPA), 15-18  
Women’s Social and Political Union (WPSU), 8-2  
Word Memory Test (WMT), 9-10  
World Medical Association, 8-3  

WPA. See Women’s Advocacy Project  
WPSU. See Women’s Social and Political Union  
Wrongful death, 3-13  

Y  
York Retreat, 1-5  
Youngberg standard, 3-10  
Youthful offenders. See Juvenile offenders  

Z  
“Zero tolerance” policy, for prison rape,  
2-29  
Ziprasidone, 16-8  
Zolpidem, 4-7  
Zopiclone, 4-7